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INTRODUCTION: 
The central role of platelets in the pathophysiology of 
arterial vascular disease has focused attention on the 
development of effective platelet inhibitor modalities to 
mitigate the clinical consequences of atherothrombotic 
disease.1 Aspirin has been the gold standard of therapy and 
is effective in cerebral, coronary and peripheral arterial 
disease with a 25% reduction in myocardial infarction, 
stroke and vascular death. The platelet ADP receptor 
antagonists were developed to further improve the clinical 
results of therapy.2 Thienopyridines are a class of ADP 
receptor/P2Y12 inhibitors used for their anti-platelet 
activity. These are a fascinating family of aromatic 
compounds with two different heterocyclic rings which 
still continue to attract the chemical interest. These drugs 
include: Clopidogrel, Prasugrel, and Ticlopidine.3 
Atherosclerosis is a diffuse process that starts early in life, 
asymptomatically progressing through adulthood, until 
clinically manifested.4 Atherothrombotic disease is the 
result of atherosclerosis progression, and its clinical 
manifestations [acute coronary syndromes (ACS), stroke, 
etc]. These events are mostly secondary to atherosclerotic 
plaque disruption and subsequent thrombus formation.5,6 
Atherosclerosis prevention is mainly focused on the 
management of the so-called „cardiovascular risk factors‟ 
whereas thrombosis-related complications are mainly 
prevented and/or treated by antithrombotic therapies. 
At the site of vascular lesions, platelets adhere to the 
exposed matrix proteins, prompting platelet activation, 
resulting in the secretion of multiple platelet agonists 
mostly modulated by intracellular calcium release. Among 
them, ADP, thromboxane A2, thrombin, and others play a  
 
critical role in maintaining a „pro-platelet-activating‟ 
environment. In fact, the understanding of the processes of 
platelet activation/aggregation and the role of acute 
thrombus formation on the onset of ACS has led to a 
widespread use of antiplatelet therapy in cardiovascular 
disease.2 Long-term antiplatelet therapy is effective in the 
secondary prevention of vascular events in patients with 
acute coronary or cerebrovascular events who are at a high 
risk of subsequent thrombotic events.7 
ADP is released from activated platelets, erythrocytes and 
endothelial cells, and induces platelet adhesion and 
aggregation. ADP activates platelets by binding to 
membrane-bound nucleotide receptors (purinoceptors) on 
the platelet surface called P2 receptors.8 Human platelets 
possess two major G protein-coupled ADP receptors, the 
P2Y1 and P2Y12 receptors, and a third ionotropic receptor, 
P2X1. The human P2Y1 receptor is a Gq protein-coupled 
receptor that activates phospholipase C to form inositol 
triphosphate (IP3) and causes calcium to be released from 
intracellular stores. The P2Y1 receptor is necessary to 
trigger a response and initiates the formation of platelet 
pseudopodia in response to low concentrations of 
thromboxane A2 or thrombin, and transient platelet 
aggregation occurs. However, activation of the P2Y1 
receptor is insufficient for a full platelet response. The 
P2Y12, formerly known as P (2T), P2T (AC), P2Y (ADP) 
or P2Y (yc), receptor is a Gi protein coupled receptor that 
inhibits adenylyl cyclase. This results in a decreased 
platelet cyclic adenosine monophosphate (AMP) level in 
response to ADP, activating platelet glycoprotein IIb ⁄ IIIa 
(aIIbb3 integrin) receptors that bind fibrinogen, leading to 
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stabilization of platelet aggregation and enhanced platelet 
secretion. Platelets also possess a third ADP receptor, 
P2X1, which is a ligand gated ion channel that mediates 
rapid transient calcium ion influx. However, the P2X1 
receptor does not contribute to platelet aggregation.9 
Aspirin was the first effective platelet inhibitor drug to be 
identified.  
 
Figure 1: Target sites for thromboxane inhibitors, ADP receptor antagonists, GPIIb/IIIa inhibitors, and novel PAR antagonists and 
adhesion antagonists. ADP, adenosine 5=-diphosphate; TxA2, Thromboxane A2; vWF, von Willebrand factor; GP, glycoprotein 
 
Figure 1: P2Y receptors can be clearly divided into two subgroups: the Gq-coupled subtypes P2Y1 and the coupled to Gi P2Y12. P2Y1, 
which are responsible for platelet shape change and calcium mobilization, are coupled to Gq and activate phospholipase Cb(PLCb) that 
is responsible for the formation of inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG), an activator of protein kinase C 
(PKC). IP3 causes calcium mobilization from internal stores. The P2Y12 receptor couples primarily to Gai2 inhibition of adenylyl 
cyclase (AC). The subsequent decrease in cAMP production leads, in turn, to a reduction in the activation of specific protein kinases 
(PKA), which can no longer phosphorylate the VASP; VASP phosphorylation is crucial for GP IIb/IIIa receptor inhibition. The subunit 
bg activates the phosphatidylinositol 3-kinase, which is an important signaling molecule for P2Y12-mediated platelet-dense granule 
secretion and GP IIb/IIIa receptor activation. Finally, P2X1 is a gated cation channel protein activated by ATP. This activation leads to 
increased intraplatelet calcium, platelet shape change, and transient and weak platelet aggregation responses. 
Dangi et al                                     Journal of Drug Delivery & Therapeutics; 2011, 1(1): 8-16                       10 
© 2011, JDDT. All Rights Reserved 
 
Aspirin results in an irreversible modification of the 
enzyme cyclo-oxygenase rendering it incapable of 
converting arachidonic acid into thromboxane A2. The 
contribution of aspirin to the reduction of vascular 
morbidity is significant but is accompanied by several 
deficiencies. Side-effects, while generally not life-
threatening, are potentially serious. Therefore, the 
development of new agents has been an appropriate and 
compelling goal. 
Thienopyridines is platelet adenosine diphosphate (ADP) 
receptor antagonists that were initially developed to 
provide new opportunities for those patients who are 
intolerant, resistant, or have failed to respond to other 
treatments. Clopidogrel (the most widely used 
thienopyridine) are considered weak and safe anti-platelet 
agent because it only blocks one of the multiple pathways 
involved in platelet activation. The thienopyridine 
derivatives inhibit ADP-induced platelet activation. They 
produce synergistic effects because they block 
complementary pathways of platelet aggregation without 
blocking thrombin-mediated platelet aggregation. In 
contrast, glycoprotein IIb ⁄ IIIa antagonists block 
aggregation induced by all agonists by preventing cross-
linkage of fibrinogen mediated platelet aggregations. 
The ADP receptor mediates platelet aggregation primarily 
through P2Y12 receptors, and to a lesser extent through 
P2Y1 receptors.
10 Thienopyridines inhibit ADP receptors 
through noncompetitive antagonism of the P2Y12 receptor, 
which in turn inhibits platelet response to other stimuli for 
platelet aggregation (eg, thromboxane A2, thrombin). Via 
transformation of the GPIIb/IIIa receptor, P2Y12 blockade 
precludes the activated platelet from releasing 
inflammatory and prothrombotic mediators as well as 
preventing platelet aggregation.11 The current agents that 
are Food and Drug Administration (FDA)-approved and 
available include ticlopidine, clopidogrel, and prasugrel. 
PHARMACOLOGY 
Pharmacokinetics of thienopyridines 
The chemical structures of clopidogrel and ticlopidine are 
very similar. Clopidogrel has an additional carboxymethyl 
side group. Ticlopidine and clopidogrel are inactive in 
vitro.  They are prodrugs and are metabolized in the liver 
by hepatic cytochrome P450-1A to produce active 
metabolites that inhibit platelet aggregation by selective 
and irreversible binding (via covalent bonds) to the P2Y12 
receptors.12 The active metabolite of clopidogrel is a thiol 
derivative of the parent molecule.13 Inhibition of platelet 
aggregation by these drugs is delayed until 24–48 h after 
administration, with maximal inhibition achieved after 3–5 
days. Recovery of platelet function after drug withdrawal 
is slow (7–14 days).  Clopidogrel, the S-enantiomer of a 
racemic thienopyridine compound (PCR 4099), is six 
times more potent than ticlopidine and does not share any 
common metabolites with ticlopidine.14 Between 60 and 
70% of the ADP receptors are sensitive to the effects of the 
thienopyridines. Maximal inhibition of ADP-induced 
platelet aggregation after a single oral dose of clopidogrel 
375–400 mg is 40–50% and is achieved in 2–6 h. This 
level of inhibition is achieved after 3–7 days of repeated 
dosing with clopidogrel 75 mg administered once daily.15 
In healthy human volunteer studies, maximal inhibition of 
platelet aggregation causes a twofold increase in the 
bleeding time. Platelet function recovers completely 7 days 
after the discontinuation of clopidogrel therapy in healthy 
volunteers. 
About 50% of ingested clopidogrel is absorbed rapidly 
from the gastrointestinal tract and is rapidly hydrolyzed in 
the liver to the main (85%) inactive metabolite (a 
carboxylic acid derivative, SR 26334), its bioavailability is 
unaffected by food or antacids.16The active metabolite has 
been identified only recently.17 Unchanged clopidogrel in 
the plasma may be detected for only 2 h after ingestion. 
The renal clearance of the principal metabolite (SR 26334) 
is constant over a clopidogrel dose range of 50–150 
mg.day, indicating that clopidogrel has linear 
pharmacokinetics. The elimination half-life of SR 26334 is 
8 h in young healthy volunteers.18 Steady-state 
pharmacokinetics can be achieved with an average of 8 
days of oral administration.19, 20 In patients with renal 
failure, bleeding times are not prolonged with standard 
doses of clopidogrel, although the renal clearance of the 
inactive metabolite SR 26334 is decreased significantly in 
patients with severe renal failure. The effect on ADP-
mediated platelet aggregation by clopidogrel is not 
affected by liver disease.21 Ticlopidine is rapidly and 
extensively absorbed from the gastrointestinal tract with an 
oral bioavailability of 80%. Ticlopidine is also 
metabolized by the hepatic cytochrome P450-1A 
isoenzyme.22 The plasma level of the major metabolite 
peaks 2 h after oral administration.23 
SYNTHESIS AND DIAGNOSIS 
Synthetic and theoretical interest in the behavior of 
systems that contain fused π rich and π deﬁcient ring as 
well as the search for pharmacologically active substances 
led to the synthesis of various analogs of quinolines and 
isoquinolines in which the benzene ring is replaced by 
thiophene nucleus. Most of the substances described in the 
literature for thienopyridines systems have been 
synthesized by traditional methods used to build quinoline 
and isoquinoline systems. 24 Recently, a tandem aza–
Wittig/electrocyclic ring closure strategy (TAWERS) was 
used to obtain this nucleus by reacting key imino-
phosphorane intermediate with isocyanates or 
isothiocyanates. Because the interest in preparing novel 
thiophene analogs of biologically active benzocompounds. 
We used a modiﬁcation of the TAWERS by reaction of the 
imino-phosphorane intermediate with aromatic and 
heteroaromatic aldehydes to afford biaryl compounds 
which would display interesting conformational properties. 
There is so much literature available that describes the 
synthesis of novel thienopyridines as well as their 
conformational analysis established by 1D and 2D NMR 
and X-ray crystallographic studies.3  
The Vilsmeier-Raack reaction is a mild but efficient 
method for the formylation of reactive aromatic substrates. 
Occasionally, unexpected cyclizations are noted 
accompanying or following such formylations. This 
method was applied to the corresponding thiophen giving 
the thienopyridine. 
But attempts to extend the reaction to 3-acetamidothiophen 
led to a mixture of products. 25  
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SEPARATION 
Acid extraction 
The measured relative basicity of compounds permits a 
rationalization of a number of analytical and synthetic 
separations which have been made for these compounds. 
Chromatography on alumina  
Many mixtures of isomeric thienopyridines and their 
derivatives have been separated by column, thin layer, or 
preparative thin layer chromatography on alumina. On the 
basis of the measured pK, values, these separations can be  
 
rationalized in terms of interaction between the 
thienopyridine compound as a Lewis base and the 
adsorbent as a Lewis acid. The stronger base is retained 
more tenaciously.26, 27 
Ticlopidine 
Ticlopidine is a first-generation thienopyridine. It was 
originally developed in the 1970s and studied as an anti-
inflammatory agent. However, its potent antiplatelet 
effects were more notable. 
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Mechanism of Action 
It irreversibly inhibits the ADP receptor, preventing 
platelet aggregation for the life of the platelet.28Despite its 
efficacy as an ADP receptor antagonist, the wide use of 
ticlopidine was significantly affected by a rare but severe 
incidence of neutropenia (8%). For these reasons, 
clopidogrel, a new agent structurally similar to ticlopidine, 
but with fewer side-effects (severe neutropenia in 0.5%) 
emerged as new antiplatelet therapy. 
Conclusions 
Dual-antiplatelet therapy with ticlopidine is rarely used, as 
clopidogrel seems to be more effective and better tolerated.  
Clopidogrel 
Clopidogrel is a second-generation thienopyridine. 
Mechanism of Action  
Like ticlopidine, it selectively and irreversibly inhibits the 
P2Y12 receptor. Clopidogrel undergoes a process of 
oxidation by the cytochrome P450 system to generate its 
active metabolite. There are many datasets demonstrating 
clopidogrel‟s benefits in high-risk patients. Clopidogrel 
plays an important role in the treatment of heart attacks 
and is used in the following situations: 
 Clopidogrel is used instead of aspirin in patients who 
have an allergy to aspirin. 
 Clopidogrel often is given together with aspirin in 
treating heart attacks. Studies have shown that the 
combination of aspirin and clopidogrel is more 
effective than aspirin alone in improving survival and 
limiting damage to heart muscle among patients with 
heart attacks. 
 Clopidogrel is given together with aspirin to patients 
undergoing PTCA with or without coronary stunting. 
Studies have shown that the combination of aspirin 
and clopidogrel is more effective than aspirin alone 
in preventing formation of blood clots that can re-
occlude the coronary artery unblocked by PTCA and 
in preventing blood clots within recently placed 
stunts. 
 After a heart attack or after PTCA, aspirin is given 
indefinitely. The optimal duration of clopidogrel has 
not been established, and duration of use by 
physicians varies from weeks to months. 
 clopidogrel has almost replaced ticlopidine as a 
therapeutic antiplatelet agent, used alone or in 
combination with aspirin. It has proved useful for the 
prevention of ischemic stroke, myocardial infarction, 
and vascular death in patients with symptomatic 
atherosclerosis.  Beyond its anti-aggregation effect, it 
reduces the formation of platelet–leukocyte 
conjugates in patients with ACS41 and decreases the 
expression of activated platelet-dependent 
inflammatory markers such as CD40 ligand (a potent 
stimulus of vascular inflammation) and CD62 P-
selectin in patients undergoing percutaneous 
coronary intervention (PCI). In fact, clopidogrel, co-
administered with aspirin, is being considered the 
treatment of choice for prevention of 
atherothrombotic complications.1  
 Resistance and Dosing 
Clopidogrel dosing has been a concern, giving significant 
variability in patient responsiveness. Many patients with 
hypo responsiveness have been called “clopidogrel 
resistant”.29, 30 First, clinical features, such as diabetes, 
have been associated with higher pretreatment platelet 
reactivity, which may not be sufficiently suppressed by 
recommended doses of clopidogrel. This observation 
coupled with the fact that insulin alters platelet reactivity 
might partially explain why diabetics fare worse after 
ACS.31-33 Second; clopidogrel activation requires the 
cytochrome P450 enzymatic system, which is affected by 
many other drugs. Therefore, there is potential for drug– 
drug interactions with clopidogrel.34 Finally, there are 
certain cellular and genetic factors that appear to underlie a 
subset of patients who are considered “clopidogrel low 
responders” or “clopidogrel resistant.35 A higher loading 
dose of 600 mg achieves full antiplatelet effect in 1-2 
hours v/s at least 4-6 hours with 300 mg, without a 
significant increase in major bleeding.36 A higher loading 
dose reduced the primary endpoint of death, MI, or TVR 
within 30 days, driven primarily by a reduction in per 
procedural MI. 
This suggests the possibility of counteracting the increased 
risk for bleeding during and after surgery in clopidogrel-
treated patients by administering platelet units prior to the 
major surgeries. 
Conclusion 
Clopidogrel in combination with aspirin has become the 
standard of care for reducing cardiovascular events in 
patients with ACS. The ACC/AHA guidelines recommend 
clopidogrel for 12 months in the setting of DES 
implantation for ACS, and at least 1 month with BMS 
implantation.37-39  
Prasugrel 
Prasugrel (CS-747; LY-640315) is a novel, third-
generation oral thienopyridine. Laboratory results with 
prasugrel support more potent antiplatelet effects, a lower 
incidence of interpatient variability in antiplatelet 
response.40  
Mechanism of Action  
It is a specific, irreversible antagonist of the platelet 
adenosine 5′-diphosphate P2Y 12 receptor. It is also a 
prodrug that acts as an irreversible inhibitor of the platelet 
ADP P2Y12 receptor. In contrast with clopidogrel, 
prasugrel is converted to its active metabolite much more 
efficiently. Therefore, prasugrel is faster acting and more 
potent, with less individual variability. Its rapid absorption 
and metabolism yields maximal concentrations in a median 
time of 30 minutes.41, 42  
Conclusions 
Prasugrel was recently approved by the FDA. The greater 
potency yielded greater efficacy but also more bleeding. 
First, clopidogrel exhibits substantial interpatient 
variability. Second, clopidogrel is rather inefficient as a 
prodrug. Eighty-five percent of its prodrug is hydrolyzed 
by esterases down a deadend pathway; therefore, only 15% 
is made available to the cytochrome P450 system for 
conversion to active metabolite. Third, recovery of platelet 
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function is relatively prolonged after clopidogrel 
administration. Due to these factors, a number of patients 
on clopidogrel and aspirin continue to experience 
cardiovascular events.1  
Side effects 
Clopidogrel has a more favourable side effect profile than 
ticlopidine. Gastrointestinal problems are the commonest 
side effects. Clopidogrel is better tolerated than 
aspirin.43Clinically severe rashes are more common with 
clopidogrel than with aspirin. Clinically significant 
gastrointestinal side effects are less frequent with 
clopidogrel than with aspirin: indigestion ⁄ nausea ⁄ 
vomiting (15 v/s. 17.6%), diarrhea (4.46 vs. 3.34%) and 
gastrointestinal hemorrhage (0.49 vs. 0.71%). Overall, the 
frequency of bleeding is similar for aspirin and clopidogrel 
(9.27 vs. 9.28%).43,44 Neutropenia was rare and was less 
frequent in the clopidogrel group than in the aspirin 
group.45 The adverse effects of ticlopidine are similar to 
those of clopidogrel, except for neutropenia. Neutropenia 
generally occurs within three months of therapy and is 
usually reversed when the drug is discontinued. Strict 
haematological monitoring (every two weeks during the 
first three months of treatment) is therefore recommended 
for patients on ticlopidine .44 The lower rate of neutropenia 
and the more favourable pharmacokinetic profile of 
clopidogrel make it the ADP receptor antagonist of choice. 
The most frequent side effects of ticlopidine are diarrhea 
and rashes. These occurred in 20% of patients in the 
Ticlopidine Aspirin Stroke Study and in 2% of patients 
were severe enough to make patients discontinue 
ticlopidine.45 
GI bleeding among patients receiving antiplatelet therapy 
can develop from many different lesions and anatomic 
sites. Upper GI bleeding may be due to esophagitis46 or 
peptic ulcer disease related to H. pylori infection, use of 
anticoagulants, steroids, or NSAIDs47 has also been shown 
to be consistent predictors for GI bleeding. These mucosal 
breaks are aggravated by the antiplatelet effects of 
thienopyridines, promoting bleeding. Several risk factors 
for GI bleeding in the setting of antiplatelet therapy have 
been reported consistently.48-55Advanced age also 
significantly increases the absolute risk of upper GI 
bleeding. The risk of GI bleeding associated with 
thienopyridines has been assessed in several case-control 
studies. Dual antiplatelet therapy with clopidogrel and 
aspirin increased the risk of GI bleeding by 2- to 3-fold 
compared with aspirin alone in randomized trials, but the 
absolute risk increase was in the range of 0.6% to 2.0%. In 
studies of varying duration and design, the case fatality 
rates for GI bleeding associated with  dual antiplatelet 
therapy have been low (0% to 0.3%). Nevertheless, the 
relative risk (RR) for death from a GI bleed has been 
estimated at 2.5,56 and GI bleeding appears to be a 
significant predictor of death, even after adjustment for CV 
morbidity, age, sex, diabetes, PCI status, and concomitant 
therapy.56, 57 
STRATEGIES TO PREVENT THIENOPYRIDINE-
RELATED UPPER GI BLEEDING 
Thienopyridines do not cause ulcers or erosions of the 
digestive tract58 but their antiplatelet effects may promote 
bleeding at the site of preexisting lesions. Upper GI 
bleeding in the setting of thienopyridine use may be 
reduced by suppressing gastric acid production, thereby 
promoting healing of peptic ulcers and mucosal erosions, 
as well as by stabilizing thrombi.59 Acid production can be 
suppressed either by H2RAs or by PPIs; the efficacy of 
each has been examined to prevent GI bleeding related to 
antiplatelet use.60 
Histamine H2 Receptor Antagonists 
The use of H2RAs can suppress gastric acid production by 
37% to 68% over 24 hours. 61-62  
Proton Pump Inhibitors 
The FDA recently released an early communication 
concerning a safety review of clopidogrel in the setting of 
proton-pump inhibitors. Patients randomized to 
omeprazole in addition to clopidogrel and aspirin had 
significantly decreased clopidogrel platelet inhibitory 
effects. 
PPIs reduce gastric acid secretion for up to 36 hours. 63 
Observational data suggest that PPIs reduce the risk of GI 
bleeding in patients on antiplatelet therapy. 
Drug Interactions 
The combination of aspirin and the thienopyridine 
derivatives causes synergistic antiplatelet effects. 
Similarly, the thienopyridines enhance the platelet-
inhibiting effects of the glycoprotein IIb ⁄ IIIa receptor 
antagonists. A pharmacokinetic interaction (mediated by 
CYP2C9) causing an intracerebral hemorrhage in an 
elderly patient with atrial fibrillation was reported with the 
concomitant use of celecoxib and clopidogrel.64 Phenytoin 
toxicity has been reported when combined with 
ticlopidine, probably caused by inhibition of its 
metabolism.65 Increased plasma concentrations of 
theophylline and carbamazepine have also been reported. 
66 
Combinations of Antiplatelet Agents 
• Aspirin and Thienopyridines  
• Aspirin and Dipyridamole  
• Combinations of Antiplatelet Agents with Anticoagulants  
It has been previously commented that aspirin and 
clopidogrel could be considered as weak antiplatelet agents 
with completely different mechanisms of action. This 
observation suggested the possibility of combining two 
weak and safe antiplatelet agents with the assumption of 
achieving stronger antiplatelet effect but still being safe. 
Aspirin exerts its antiplatelet effects by acetylating the 
serine moiety at position 529 of COX-1 and thereby 
irreversibly inhibiting the key enzyme required for the 
conversion of arachidonic acid to TXA2. As mentioned 
earlier, TXA2 is a potent platelet activating agent and 
results in platelet shape change, secretion of granular 
contents, and increased expression of GPIIb/IIIa receptors 
by binding to its cell surface receptor. Because platelets 
lack nuclei, they are unable to synthesize new COX-1 and 
are, therefore, permanently inhibited by aspirin. Despite 
being a relatively „weak‟ antiplatelet agent, aspirin remains 
a frontline therapy with proven benefits in primary and 
secondary prevention of coronary artery disease (CAD). 
 As has been clearly depicted, there are many other platelet 
receptors different from the TXA2 receptor that can 
Dangi et al                                     Journal of Drug Delivery & Therapeutics; 2011, 1(1): 8-16                       14 
© 2011, JDDT. All Rights Reserved 
 
activate platelets and amplify platelet response upon 
agonist binding. Therefore, it is intuitive to think that other 
compounds that block these other receptors could exert 
additional benefits to aspirin monotherapy. This 
underscores the need to continue the search for new agents 
that can either replace or be used in addition to aspirin for 
short- and long-term management. In fact, inhibition of the 
platelet P2Y12 ADP-receptor by clopidogrel on a 
background of TXA2 inhibition by aspirin has proved an 
enhancement in platelet inhibition.  
Patients who are resistant to aspirin (up to 10%) have 
higher rates of cardiovascular events and may derive 
special benefit from the combination therapy. On the other 
hand, the co-administration of different antiplatelet 
therapies that act at different targets also increases the risk 
of bleeding. This complex equilibrium has to be taken into 
account when dual antiplatelet therapy is planned. Despite 
all this, current clinical recommendations for patients 
undergoing PCI suggest loading dose regimens of 300–600 
mg clopidogrel plus aspirin with a maintenance daily dose 
of 75 mg of clopidogrel. 
New Antiplatelet Strategies 
• Direct Thrombin Inhibitors  
• Antiplatelet Effects of Polyunsaturated Fatty Acids and 
Prostacyclin  
• Nitric Oxide Derivatives as Antiplatelet Agents  
• Soluble CD39 as an Antiplatelet Agent that Inhibits 
Released ADP  
• Simultaneous Blockade of Platelet P2Y12 and P2Y1 ADP 
Receptors 
 
SUMMARY AND CONCLUSION 
Atherothrombosis is the basis for the epidemic rates of 
acute cerebrovascular, coronary and peripheral vascular 
morbidity and mortality. Antiplatelet therapy plays a 
central role in management. Aspirin has been the mainstay; 
the thienopyridines provide new opportunities for those 
patients who are intolerant, resistant or have failed to 
respond to aspirin, and for those who can derive greater 
beneﬁt from combined therapy. The patient subgroups that 
beneﬁt the most and cost-effectiveness concerns remain 
matters for further assessment. Due to its equivalence to 
ticlopidine, its greatly improved side-effect proﬁle over 
ticlopidine, and its once-daily dosing, clopidogrel is the 
thienopyridine of choice. 
Gastrointestinal side effects and skin rashes are common. 
However, neutropenia and thrombotic thrombocytopenic 
purpura are significant and sometimes fatal adverse effects 
of ticlopidine. Clopidogrel appears to offer several 
advantages over ticlopidine: a more rapid onset of action 
 
 
 and a lower incidence of neutropenia and thrombotic 
thrombocytopenic purpura. 
However, clopidogrel should be used with caution in 
patients with severe hepatic dysfunction because of 
increased bleeding risks associated with coagulation 
disturbances in liver failure. There is no information on the 
use of clopidogrel in pregnant or lactating women. There 
are several limitations to clopidogrel. Prasugrel, a third-
generation oral thienopyridine, overcomes some of these 
limitations, although this was associated with a greater risk 
of bleeding. 
With the clinical trials of the thienopyridine drugs under 
way, it is likely that the number of patients receiving these 
drugs will increase. An understanding of the pharmacology 
of the thienopyridine derivatives is essential for the 
anesthetist so that the peri-operative management surgical 
patients can be optimized. 
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